奥氮平附加倍他司汀治疗对慢性精神分裂症患者认知功能的影响

Effects of olanzapine plus betahistine on cognitive function in patients with chronic schizophrenia

目的 研究奥氮平附加倍他司汀治疗对慢性精神分裂症患者认知功能的影响。方法 入组50例慢性精神分裂症患者,其中奥氮平附加倍他司汀治疗的25例患者为研究组,奥氮平附加安慰剂治疗的25例患者作为对照组,分别于基线及治疗后第4、8、12周末采用阳性与阴性症状量表(PANSS)对患者的精神病性症状进行系统评估;采用临床疗效总评量表(CGI)评估疾病严重程度;采用精神分裂症认知功能成套测验(MCCB)对精神分裂症患者的认知功能进行系统评估;采用治疗不良反应量表(TESS)评估治疗不良反应。结果 两组MCCB总分及信息处理速度、工作记忆、言语记忆、视觉记忆、推理与问题解决在时间效应上比较,差异存在统计学意义(P<0.001),工作记忆、视觉记忆时间*组别效应上比较,差异存在统计学意义(P<0.05)。两组PANSS总分及阴性症状评分在时间效应上比较,差异有统计学意义(P<0.05)。两组总不良反应发生率比较,差异无统计学意义(P>0.05)。结论 奥氮平附加倍他司汀治疗对慢性精神分裂症患者工作记忆、视觉记忆等认知功能可能具有改善作用。

Objective To explore the effect of olanzapine plus betahistine on cognitive function in patients with chronic schizophrenia. Methods A total of 50 patients with chronic schizophrenia were selected and divided into study group(25 cases) treated with olanzapine combined with betahistine and control group(25 cases) treated with olanzapine combined with placebo. They were all assessed with Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), MATRICS Consensus Cognitive Battery(MCCB) and Treatment Emergent Symptom Scale(TESS) before and after treatment. Results There existed significant differences on the time effects in the total score and information processing speed, working memory, verbal memory, visual memory, reasoning and problem solving of MCCB, as well as in the total score and negative symptom score of PANSS between two groups(P<0.05). There existed significant differences on the time * group effects in working memory and visual memory of MCCB between two groups(P<0.05). There was no significant difference in the incidence of adverse reactions between two groups(P>0.05). Conclusion Olanzapine combined with betahistine can improve the cognitive function of working memory, visual memory in patients with chronic schizophrenia.